The ERS Congress 2024
The European Respiratory Society (ERS) Congress is an annual academic conference, renowned as one of the two most important global events focusing on respiratory and thoracic disease treatment. In 2024, the event will be held as an in-person international conference in Vienna. The Congress covers a broad range of topics, with 7-10 simultaneous sessions taking place at any given time.
Our collaborative research with National Tsing Hua University has achieved a significant breakthrough and was honored to present its preliminary findings on the “Evaluating the clinical potential of inhalation of umbilical cord mesenchymal stem cell (UC-MSC) exosomes in pulmonary fibrosis (PF) treatment.” during this prestigious event. The presentation garnered considerable attention and discussions from attendees and has been featured on the official ERS website.
What is Pulmonary Fibrosis?
Pulmonary fibrosis (PF) is a severe lung disease characterized by scarring of lung tissue, The condition occurs when fibroblasts lose regulation during the healing process following lung injury, leading to tissue hardening and gradual loss of function. As a result, the lungs lose their elasticity, and thickened alveolar walls hinder efficient gas exchange. This can cause symptoms such as breathlessness, dry cough, and difficulty breathing.
Without effective treatment, the disease often progresses, leading to high-mortality complications. Currently, pulmonary fibrosis is irreversible, and available medications can only slow its progression. The only definitive cure is lung transplantation, which comes with potential risks such as complications or rejection.
For more information:【Medical Insight】 Can Pulmonary Fibrosis Still be Treated? Explore all the Current Treatment Methods for Pulmonary Fibrosis!
Landmark Research: “Evaluating the clinical potential of inhalation of umbilical cord mesenchymal stem cell (UC-MSC) exosomes in pulmonary fibrosis (PF) treatment.”
This study demonstrates that ubExosome treatment effectively interrupts the progression of PF disease animal model. By alleviating the reciprocal exacerbation of weight loss and lung function deterioration, ultimately leading to a reduction in mortality rate.
In our study, aerosolized ubExosomes proved to be an effective, non-invasive treatment for PF, demonstrating superior efficacy compared to invasive intravenous delivery.
Looking forward, we will continue our close collaboration with National Tsing Hua University to optimize this innovative therapy. Future research will focus on establishing safe dosage guidelines, refining aerosol particle size distribution, and improving nebulization equipment to enhance therapeutic outcomes. These efforts will pave the way for clinical trials and align with our company’s vision and objectives.
For more details: ERS Publications
Attached: Poster Presentation and Chinese Translation of the Paper.
